The latest findings in cancer vaccine development suggest that cancer vaccines may have two modes of action; specific immunization and non-specific activation of immune cells paralyzed by the tumor.
The human immune system fights cancer partly through the production of many populations of specialized immune cells called cytolytic T cells (CTL). Each CTL population recognizes a different, specific marker, an antigen, on the cancer cell surface. Cancer vaccines are designed to tip the balance in favor of the immune system by stimulating the production of CTLs against the particular antigen in the vaccine. However, in back-to-back articles published today in the Journal of Experimental Medicine, investigators at the Brussels Branch of the Ludwig Institute for Cancer Research (LICR) and Brussels Louvain University have shown that a cancer vaccine not only specifically stimulates the production of CTLs against the vaccine antigen, it also non-specifically activates spontaneously produced CTL populations against multiple cancer antigens.
According to Dr. Thierry Boon, the Director of the LICR Brussels Branch, this observation opens a new way of thinking about how cancer vaccines might work. "We have always thought that cancer vaccines could only be effective if massive numbers of vaccine-specific CTLs were produced. But it seems that, in about 10% of patients with metastatic melanoma, the vaccine might actually be reawakening different CTL populations that have been effectively deactivated by the tumor."
Sarah L. White | EurekAlert!
World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern
Therapy of preterm birth in sight?
19.07.2017 | Universitätsspital Bern
21.07.2017 | Event News
19.07.2017 | Event News
12.07.2017 | Event News
21.07.2017 | Earth Sciences
21.07.2017 | Power and Electrical Engineering
21.07.2017 | Physics and Astronomy